Huvexxin 100 mg/ml solution for injection for cattle, pigs and sheep

Authorised

- Tulathromycin

Product identification

Medicine name:
Huvexxin 100 mg/ml solution for injection for cattle, pigs and sheep
Huvexxin 100 mg/ml Stungulyf, lausn Handa nautgripum, svínum, kindum

Active substance:
Tulathromycin

Target species:
Sheep
Pig
Cattle

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:

Tulathromycin
100.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Sheep**
  - Meat and offal. 16 day

- **Pig**
  - Meat and offal. 13 day

Subcutaneous use:

- **Cattle**
  - Meat and offal. 22 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01FA94

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Iceland

Package description:
Type I colourless glass vial with a chlorobutyl rubber stopper and an aluminium overseal.Pack sizes: Cardboard box containing one vial of 100 ml.
Type I colourless glass vial with a chlorobutyl rubber stopper and an aluminium overseal.Pack sizes: Cardboard box containing one vial of 20 ml.

Type I colourless glass vial with a chlorobutyl rubber stopper and an aluminium overseal.Pack sizes: Cardboard box containing one vial of 250 ml.
Type I colourless glass vial with a chlorobutyl rubber stopper and an aluminium overseal.Pack sizes: Cardboard box containing one vial of 50 ml.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
HuVepharma

Marketing authorisation date:
26/04/2023

Manufacturing sites for batch release:
Biovet AD

Responsible authority:
Icelandic Medicines Agency

Authorisation number:
IS/2/23/007/02

Date of authorisation status change:
26/04/2023

Reference member state:
Ireland

Procedure number:
IE/V/0662/002

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia France

Germany Greece Hungary Iceland Italy Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics